Effect of thymosin α1 on Immune response and organ function in acute aortic dissection surgery: PANDA II trial protocol.
Liu. Hong H; Qian. Si-Chong SC; Zhang. Ying-Yuan YY; Tang. Cheng-Bin CB; Yue. Hong-Hua HH; Fan. Guo-Liang GL; Zhao. Xin X; Jiang. Yi-Yao YY; Huang. Fu-Hua FH; Zeng. Zhi-Hua ZH; Wang. Wei W; Lu. Xu-Ran XR; Luo. Xiao-Kang XK; Bai. Xiang-Feng XF; Zheng. Xiang-Xiang XX; Xie. Peng P; Ma. Chao C; Zhao. Sheng S; Zhang. Hong-Jia HJ
Key Findings
- The study will enroll about 330 patients with acute type A aortic dissection.
- Participants will be randomly given thymosin‑alpha‑1 plus standard care or a placebo plus standard care.
- The main outcome is the difference in average daily SOFA scores (a measure of organ failure) after surgery.
Practical Outcomes
- Because this is only a trial protocol, there are no actionable dosing or usage recommendations for biohackers at this time. Keep an eye on future publications from this trial for any evidence that thymosin‑alpha‑1 might help reduce post‑surgical inflammation and organ injury.
Summary
This abstract describes a planned clinical trial that will test whether giving the peptide thymosin‑alpha‑1 to patients after emergency surgery for a torn aorta can lower organ damage by calming the immune system. No results are available yet, so we don’t know if it works.
Abstract
This multicenter randomized controlled trial evaluates the efficacy of thymosin alpha 1 (Tα1) supplementation in preventing organ dysfunction following acute type A aortic dissection (ATAAD) repair. Over 330 patients will be equally assigned to receive either Tα1 plus standard care or placebo with standard management. The primary endpoint involves calculating the difference in mean postoperative Sequential Organ Failure Assessment (SOFA) scores between groups, measured daily from postoperative days 7. By targeting post-operative immune system imbalance, this study aims to establish a novel therapeutic approach for reducing systemic inflammatory response syndrome (SIRS)-mediated organ injury and improving long-term outcomes in this high-risk population. Results will be disseminated through peer-reviewed publications and international conferences.<b>Trial registration</b>: ClinicalTrials.gov Registry (NCT05339529).
Study Information
pubmed
2025
2025-05-14T00:00:00.000Z
10.1080/14796678.2025.2505401
1
24